Different Doses of Naronapride vs. Placebo in Gastroparesis
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II
dose-finding trial. The trial will be conducted with four treatment groups in the form of a
parallel group comparison and will serve to compare oral treatment with daily doses of 10,
20, or 40 mg Naronapride vs. placebo for the treatment of patients with Gastroparesis.